

---

**From:** CAC (Consumer Advisory Committee)  
**Sent:** Sunday, 4 December 2022 12:01 pm  
**To:** CAC Members; 'Tui Taurua'  
**Subject:** Confidential consultation  
**Attachments:** 2022-12 Proposal to fund elexacaftor with tezacaftor and ivacaftor (Trikafta) for people with cystic fibrosis.pdf

Kia ora koutou

Please find attached a confidential copy of consultation for a proposal to fund elexacaftor with tezacaftor and ivacaftor (brand name Trikafta) for people with cystic fibrosis aged 6 years and above who meet certain eligibility criteria. This is **confidential until public release at 6 pm** this evening (Sunday).

From 6 pm, the consultation will be available on the Pharmac website via [this link](#).

We welcome your feedback on this proposal. To provide feedback, please submit it in writing by 5 pm, Monday 16 January 2023 to [consult@pharmac.govt.nz](mailto:consult@pharmac.govt.nz).

Ngā mihi,  
Mako

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington  
P: [REDACTED] | [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Contact details:

Mako Osborne | Ph [REDACTED]  
Peter Alsop | Ph [REDACTED]  
Jannel Fisher | Ph [REDACTED]  
Trish Elise | Ph [REDACTED]

*Te Pātaka Whaioranga – Pharmac will be closed from Saturday 24 December 2022 to Tuesday 3 January 2023 inclusive.*

---

**From:** Alex Chippy Compton  
**Sent:** Monday, 5 December 2022 8:46 am  
**To:** Consult  
**Subject:** FW: Consultation on a proposal to fund elexacaftor with tezacaftor and ivacaftor (Trikafta)

Ngā mihi

Chippy Compton | [she/her](#) | Therapeutic Group Manager

---

Te Pātaka Whaioranga | Pharmac | PO Box 10-254 | Level 9, 40 Mercer Street, Wellington  
DDI: [REDACTED] | P: [REDACTED] | M: [REDACTED] | [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

---

**From:** Ben Graham <[REDACTED]>  
**Sent:** Sunday, 4 December 2022 12:12 pm  
**To:** Alex Chippy Compton <[REDACTED]>  
**Subject:** FW: Consultation on a proposal to fund elexacaftor with tezacaftor and ivacaftor (Trikafta)

---

**From:** [REDACTED]  
**Sent:** Sunday, 4 December 2022 12:04 pm  
**To:** Ben Graham <[REDACTED]>; Anti-Infective Advisory Committee <[Anti-Infective@Pharmac.govt.nz](mailto:Anti-Infective@Pharmac.govt.nz)>  
**Subject:** Re: Consultation on a proposal to fund elexacaftor with tezacaftor and ivacaftor (Trikafta)

!



---

**From:** Ben Graham <[REDACTED]>  
**Sent:** Sunday, December 4, 2022 12:00 PM  
**To:** Anti-Infective Advisory Committee <[REDACTED]>  
**Subject:** Consultation on a proposal to fund elexacaftor with tezacaftor and ivacaftor (Trikafta)

Kia ora Anti-Infective Advisory Committee,

Please find attached a confidential copy of consultation for a proposal to fund elexacaftor with tezacaftor and ivacaftor (brand name Trikafta) for people with cystic fibrosis aged 6 years and above who meet certain eligibility criteria. This is **confidential until public release at 6 pm, 4th December** (Sunday).

From 6 pm, the consultation will be available on the Pharmac website via [this link](#).

We welcome your feedback on this proposal. To provide feedback, please submit it in writing by 5 pm, Monday 16 January 2023 to [consult@pharmac.govt.nz](mailto:consult@pharmac.govt.nz).

Ngā mihi

Ben Graham | Therapeutic Group Manager | Operations Directorate

---

Te Pātaka Whaioranga | Pharmac | PO Box 10-254 | Level 9, 40 Mercer Street, Wellington  
P: 0800 660 050 M: [REDACTED] | [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

*Te Pātaka Whaioranga – Pharmac will be closed from Saturday 24 December 2022 to Tuesday 3 January 2023 inclusive.*

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

---

**From:** Alex Chippy Compton  
**Sent:** Sunday, 4 December 2022 12:04 pm  
**To:** Mark O'Carroll  
**Cc:** Logan Heyes  
**Subject:** RE: Upcoming Pharmac consultation  
**Attachments:** Confidential - Proposal to fund elexacaftor with tezacaftor and ivacaftor (Trikafta) for people with cystic fibrosis.pdf

Kia ora,

Later today, we will be releasing consultation on a proposal to fund elexacaftor with tezacaftor and ivacaftor (brand name Trikafta) for people with cystic fibrosis aged 6 years and above who meet certain eligibility criteria. Please find attached a confidential copy of our consultation. This is **confidential until public release at 6 pm** this evening (Sunday).

From 6 pm, the consultation will be available on the Pharmac website via [this link](#). Following public release, you are welcome to share the link with others who may be interested.

We welcome your feedback on this proposal. To provide feedback, please submit it in writing by 5 pm, Monday 16 January 2023 to [consult@pharmac.govt.nz](mailto:consult@pharmac.govt.nz).

Thank you for your advice on and advocacy for this funding proposal. Please let me know if you have any questions.

Ngā mihi,  
Chippy

Ngā mihi

Chippy Compton | [she/her](#) | Therapeutic Group Manager

---

Te Pātaka Whaioranga | Pharmac | PO Box 10-254 | Level 9, 40 Mercer Street, Wellington  
[www.pharmac.govt.nz](http://www.pharmac.govt.nz)

---

**From:** Alex Chippy Compton  
**Sent:** Friday, 2 December 2022 4:43 pm  
**To:** Mark O'Carroll <[REDACTED]>  
**Cc:** Logan Heyes <[REDACTED]>  
**Subject:** Upcoming Pharmac consultation

Kia ora koutou,

I wanted to let you know that this Sunday (4 December, 6 pm) Pharmac will be releasing public consultation on a funding proposal which we think will be of interest to you. I will email a confidential copy of this consultation to you on Sunday at midday ahead of public release.

Best Wishes,  
Chippy

Ngā mihi

Chippy Compton | [she/her](#) | Therapeutic Group Manager

proactive release  
21 February 2023

---

**From:** Jane Wright  
**Sent:** Sunday, 4 December 2022 3:05 pm  
**To:** David Cormack  
**Subject:** 2022-12-01 Pharmac messages to support the Trikafta consultation  
**Attachments:** 2022-12-01 Pharmac messages to support the Trikafta consultation.docx

proactive release  
21 February 2023

## Pharmac messages to support the Trikafta consultation

### *Trikafta funding messages*

- Te Pātaka Whaioranga – Pharmac has reached a provisional agreement with medicine supplier Vertex to fund Trikafta for people aged 6 years and above with cystic fibrosis who meet certain eligibility criteria.
- Trikafta is the brand name for elexacaftor with tezacaftor and ivacaftor. It is a tablet, taken twice a day.
- We received an application to fund Trikafta in July 2021, and it was added to our options for investment list in October 2021. Just over a year later, we are a step closer to funding it.
- Trikafta has the potential to make a substantial difference to the lives of those people in New Zealand living with cystic fibrosis and for their whānau and communities too.
- Trikafta could give people with cystic fibrosis up to 27 more years at full health, when compared with supportive care.
- Funding Trikafta would significantly reduce the impact of the condition on people with cystic fibrosis, their whānau and communities.
- The evidence is clear that Trikafta can benefit people with cystic fibrosis, so we are to have started consultation on a proposal to fund it.
- Funding of Trikafta is proposed to start 1 April 2023.
- There are more than 360 people in New Zealand who would be eligible for funded treatment under the proposed criteria.

### *Pharmac budget messages*

- The \$191 million pharmaceutical budget increase over two years Pharmac received in May is the biggest we've had since we were formed almost 30 years ago.
- The Budget 2022 announcement means Pharmac's budget for treatments is now \$1.186 billion and next year will be \$1.245 billion.
- We are continuing to work our way through their options for investment list, trying to secure deals for as many items as we can.
- Since 1 July 2022 Pharmac has funded 12 new treatments and widened access to 17 already funded medicines, and there are more to come.

## FAQs

### **What is happening?**

Te Pātaka Whaioranga – Pharmac has reached a provisional agreement with medicine supplier Vertex to fund Trikafta for people aged 6 years and above with cystic fibrosis who meet certain eligibility criteria.

### **Why now? I thought your CE said you wouldn't be able to afford this right now.**

All Pharmac staff are motivated to fund as many treatments as we can to achieve the best health outcomes for New Zealanders. We have been working really closely with Vertex, the supplier of Trikafta, to come to an agreement, and are thrilled we have been able to.

### **How much is it going to cost taxpayers?**

We can't share the cost that Pharmac is paying for Trikafta. We ask New Zealanders to trust that we were able to negotiate a good, fair price for a treatment that has the potential to make a substantial difference to the lives of those people in New Zealand living with cystic fibrosis and for their whānau and communities too.

### **What about everything else on your OFI list?**

We would love to be able to fund every medicine for every condition but unfortunately that's not realistic. The budget increase we got this year is the largest in our history and has allowed us to fund many more medicines.

We are continuing to work our way through their options for investment list, trying to secure deals for as many items as we can. Since 1 July 2022 Pharmac has funded 12 new treatments and widened access to 17 already funded medicines, and there are more to come.

### **Why did it take so long?**

We received an application to fund Trikafta in July 2021, and it was added to our options for investment list in October 2021. Just over a year later, we are a step closer to funding it.



proactive release  
21 February 2023

---

**From:** Jane Wright  
**Sent:** Sunday, 4 December 2022 3:31 pm  
**To:** David Cormack  
**Subject:** Re: '2022-12-01 Pharmac messages to support the Trikafta consultation' with you

Thank you!!

Get [Outlook for iOS](#)

---

**From:** David Cormack <[REDACTED]>  
**Sent:** Sunday, December 4, 2022 3:28:58 PM  
**To:** Jane Wright <[REDACTED]>  
**Subject:** '2022-12-01 Pharmac messages to support the Trikafta consultation' with you

Suggestions in red.

proactive release  
21 February 2023

---

**From:** Jane Wright  
**Sent:** Sunday, 4 December 2022 3:31 pm  
**To:** Megan Brodie  
**Subject:** RE: Trikafta funding deal

Embargoed until 6pm NZ Time tonight.



## Media release

4 December 2022

### Pharmac seeking feedback on funding Trikafta

Te Pātaka Whaioranga – Pharmac has reached a provisional agreement with medicine supplier Vertex to fund Trikafta.

“Following [our budget increase in May 2022](#) and commercial negotiations with the supplier, Vertex, I am thrilled to announce today that we are initiating consultation on the funding of Trikafta for people aged 6 years and above with cystic fibrosis who meet certain eligibility criteria,” says Pharmac’s director of operations Lisa Williams.

“Trikafta has the potential to make a substantial difference to the lives of those people in New Zealand living with cystic fibrosis and for their whānau and communities too. We estimate that, if funded, Trikafta could give people with cystic fibrosis up to 27 more years at full health, when compared with supportive care. This would significantly reduce the impact of the condition on people with cystic fibrosis, their whānau and communities.

“We have been actively working towards this step in the funding process since receiving recommendations from both our Respiratory Advisory Committee and from our Pharmacology and Therapeutics Advisory Committee (PTAC) that the medicine should be funded. Our expert advisors have told us that treatment with Trikafta significantly improves lung function and other symptoms of cystic fibrosis. The evidence is clear that Trikafta can benefit people with cystic fibrosis, so we are pleased to start consultation on a proposal to fund it.

“I want to acknowledge the time that many people have put into advocating for those living with cystic fibrosis and to those who have shared their own very personal stories with us. We have heard them all, and we know there will be a lot of people thrilled to hear that we are proposing to fund Trikafta.”

The consultation is available on the Pharmac website for anyone wanting to have their say.

“Consultation is a very important step in our process,” says Ms Williams. “It’s how we check that the people who will get the most benefit from the medicines will be able to access them. If approved, we will also be working closely with our colleagues across the health sector to plan for the implementation of Trikafta.”

“We have been saying that we wanted to fund Trikafta – and now we are a step closer,” says Ms Williams.

Funding of Trikafta is proposed to start 1 April 2023.

**ENDS**

We are welcoming feedback on the proposed funding of Trikafta until 16 January 2023. Please email [media@pharmac.govt.nz](mailto:media@pharmac.govt.nz) or call 021863342 if you would like to know more.

**Learn more:**

Trikafta is a combination of elexacaftor, tezacaftor and ivacaftor. It is a tablet, taken twice a day. Due to the wide public interest in its funding application, Pharmac has shared every milestone along our assessment and decision-making processes, starting with receiving the application:

- <https://pharmac.govt.nz/news-and-resources/news/cystic-fibrosis-medicine-applications-to-be-considered-by-pharmac-and-medsafe-in-parallel/?page=9>
- <https://pharmac.govt.nz/news-and-resources/news/2021-07-09-media-release-application-for-cystic-fibrosis-medicine-received-by-pharmac/?page=8>
- <https://pharmac.govt.nz/news-and-resources/news/2021-10-27-media-release-cystic-fibrosis-medicine-added-to-pharmacs-options-for-investment-list/?page=7>
- <https://pharmac.govt.nz/news-and-resources/news/2021-02-23-media-release-pharmacs-clinical-experts-recommend-funding-trikafta/?page=5>
- <https://pharmac.govt.nz/news-and-resources/news/2022-08-15-media-release-pharmac-shares-update-on-its-assessment-of-trikafta/?page=2>

A year and a half after receiving the application to fund Trikafta, it is only fitting that Pharmac shares this milestone too.

*We are continuing to work our way through our options for investment list, trying to secure deals for as many items as we can within available funding. Since 1 July 2022 Pharmac has funded 12 new treatments and widened access to 17 already funded medicines, and there are more to come.*

Ngā mihi

Jane Wright | Pharmac's Senior Communications Advisor, Media

---

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington  
M: [REDACTED] [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

---

**From:** Megan Brodie <[REDACTED]>  
**Sent:** Sunday, 4 December 2022 3:28 pm  
**To:** Jane Wright <[REDACTED]>  
**Subject:** Trikafta funding deal

Hey Jane

I understand you have an embargoed release for me? Send it through when you can and congrats all around on a wonderful achievement. Happy days!

Cheers,

Megan

**Megan Brodie**

Publishing Editor

m: [REDACTED]

e: [REDACTED]

w: [www.mednews.com.au](http://www.mednews.com.au)



proactive release  
21 February 2023

---

**From:** Jane Wright  
**Sent:** Sunday, 4 December 2022 4:41 pm  
**To:** Lisa Williams  
**Subject:** 2022-12-01 Pharmac messages to support the Trikafta consultation (A1638978)  
**Attachments:** 2022-12-01 Pharmac messages to support the Trikafta consultation.obr

Key messages and FAQs, including a few more curly ones

Jane Wright has sent you a link to "2022-12-01 Pharmac messages to support the Trikafta consultation" (A1638978) from Objective.

Open in Navigator  
Double click on the attachment


Open in Supported Application  
[url:objective://id:A1638978@objective.pharmac.govt.nz:8643](mailto:objective://id:A1638978@objective.pharmac.govt.nz:8643)

Open in Your Browser  
Latest: <https://objective.pharmac.govt.nz:8643/id:A1638978/document/versions/latest>  
Published: <https://objective.pharmac.govt.nz:8643/id:A1638978/document/versions/published>

---

**From:** Te Pātaka Whaioranga - Pharmac <consult@pharmac.govt.nz>  
**Sent:** Sunday, 4 December 2022 6:00 pm  
**To:** Jane Wright  
**Subject:** Pharmac consultation: proposal to fund Trikafta for people with cystic fibrosis aged 6 years and above

[View this email in your browser](#)



## Pharmac consultation: proposal to fund Trikafta for people with cystic fibrosis aged 6 years and above

Kia ora,

We are pleased to announce that we are proposing to fund elexacaftor with tezacaftor and ivacaftor (brand name Trikafta) for people with cystic fibrosis aged 6 years and above who meet certain eligibility criteria.

Please follow [this link](#) to the consultation on our website. We welcome feedback on this proposal. To provide feedback, please submit it in writing by 5 pm, Monday 16 January 2023 to [consult@pharmac.govt.nz](mailto:consult@pharmac.govt.nz).


Please circulate this to others who may be interested.

Ngā mihi,

Alex Chippy Compton | Therapeutic Group Manager

---

Te Pātaka Whaioranga | Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street,  
Wellington | P: 0800 660 050 | [www.pharmac.govt.nz](http://www.pharmac.govt.nz)



You can [update your preferences](#) or [unsubscribe from this list](#).

Find out more about Pharmac's [copyright](#)

proactive release  
21 February 2023